Back to results
US 2023/0416375 A1Published application
Antibody variants against wnt receptor ryk
AssigneeVersapeutics, Inc.
InventorsDavid N. HAUSER, Taylor L. KAMPERT, Miao SUN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to isolated anti-Ryk antibodies or antibody derivatives. In some aspects, the present disclosure relates to the use of the isolated anti-Ryk antibodies or antibody derivatives.
Claims39
An isolated anti-Ryk antibody or antibody derivative that:
- a) specifically binds to a Wnt-binding domain on Ryk or specifically binds to an epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), the antibody or antibody derivative comprising a light chain variable region comprising the CDR sequence set forth in SEQ ID NO:1 [RANRLVE];
- b) specifically binds to the same epitope on a Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk, amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), as does a reference antibody or antibody derivative, or cross-competes for specific binding to the Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk, with a reference antibody or antibody derivative, the reference antibody or antibody derivative comprising a light chain variable region comprising the CDR sequence set forth in SEQ ID NO:1 [RANRLVE];
- c) specifically binds to a Wnt-binding domain on Ryk or specifically binds to an epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), said antibody or antibody derivative comprising a heavy chain variable region comprising the CDR sequence set forth in SEQ ID NO:2 [STGGGGTY], SEQ ID NO:3 [HGDSGDY] or SEQ ID NO:4 [HGDQGDY];
- or
- d) specifically binds to the same epitope on a Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), as does a reference antibody or antibody derivative, or cross-competes for specific binding to the Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk with a reference antibody or antibody derivative, the reference antibody or antibody derivative comprising a heavy chain variable region comprising the CDR sequence set forth in SEQ ID NO:2 [STGGGGTY], SEQ ID NO:3 [HGDSGDY] or SEQ ID NO:4 [HGDQGDY],
- provided that the antibody or antibody derivative is not an isolated anti-Ryk antibody or antibody derivative disclosed and/or claimed in WO 2017/172733 A1.
3 more elements
(canceled)
5-6. (canceled)
(canceled)
10-11. (canceled)
An isolated anti-Ryk antibody or antibody derivative that:
- a) specifically binds to a Wnt-binding domain on Ryk or specifically binds to an epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), the antibody or antibody derivative comprises a light chain variable region comprising an amino acid sequence comprising at least about 85% sequence identity to SEQ ID NO:11 [VL1], SEQ ID NO:12 [VL2], or SEQ ID NO:13 [VL3];
- b) specifically binds to the same epitope on a Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), as does a reference antibody or antibody derivative, or cross-competes for specific binding to the Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk with a reference antibody or antibody derivative, the reference antibody or antibody derivative comprising a light chain variable region comprising an amino acid sequence comprising at least about 85% sequence identity to SEQ ID NO:11 [VL1], SEQ ID NO:12 [VL2], or SEQ ID NO:13 [VL3];
- c) specifically binds to a Wnt-binding domain on Ryk or specifically binds to an epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), the antibody or antibody derivative comprises a heavy chain variable region that comprises an amino acid sequence comprising at least about 85% sequence identity to SEQ ID NO:14 [VH1], SEQ ID NO:15 [VH2], SEQ ID NO:16 [VH3], SEQ ID NO:17 [VH4], or SEQ ID NO:18 [VH5];
- or
- d) specifically binds to the same epitope on a Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk, e.g., amino-acids 35-211 of mouse Ryk (SEQ ID NO:24) or amino-acids 26-227 of human Ryk (SEQ ID NO:25), as does a reference antibody or antibody derivative, or cross-competes for specific binding to the Wnt-binding domain on Ryk or the same epitope within a region of the ectodomain of Ryk with a reference antibody or antibody derivative, the reference antibody or antibody derivative comprising a heavy chain variable region that comprises an amino acid sequence comprising at least about 85% sequence identity to SEQ ID NO:14 [VH1], SEQ ID NO:15 [VH2], SEQ ID NO:16 [VH3], SEQ ID NO:17 [VH4], or SEQ ID NO:18 [VH5],
- provided that the antibody or antibody derivative is not an isolated anti-Ryk antibody or antibody derivative disclosed and/or claimed in WO 2017/172733 A1.
3 more elements
13-14. (canceled)
16-30. (canceled)
32-33. (canceled)
(canceled)
37-38. (canceled)
40-41. (canceled)
43-46. (canceled)
48-52. (canceled)
55-65. (canceled)
(canceled)
70-73. (canceled)
75-84. (canceled)
86-108. (canceled)
110-112. (canceled)
Dependencies are inferred from the claim text.